The hold does not effect making a deal; anyone who is interested in Leronlimab will know the history of years of safe use. I am still convinced that the hold is being slow walked to give someone time to get a competing drug out an indication that we cover. This is just how this business works. That said, a deal from a competitor could be struck at any time. It will happen if a BP entity gets nervous about a competitor.